Related Experiment Video
Updated: Jun 10, 2026

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
Published on: March 30, 2020
Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema
Jianmin Wang1, Mohamed Ibrahim, Peykan Turkcuoglu
1Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA.
Purpose:
To describe the bioactivity of an intercellular adhesion molecule inhibitor (efalizumab) in a patient with refractory uveitic macular edema.
Methods:
A 55-year-old man presented with idiopathic autoimmune uveitis and associated macular edema, which could not be controlled by regional and systemic corticosteroid and selected immunomodulatory therapy. Efalizumab was administered as subcutaneous injections.
Results:
After 37 weekly injections of efalizumab, the uveitic macular edema was successfully eliminated. Six months following discontinuation of efalizumab, there were no signs of recurrent inflammation.
Conclusion:
Further investigation of the role of intercellular adhesion molecule inhibitors in the management of uveitic macular edema is indicated.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Angle Closure Glaucoma: Treatment
Cytotoxic Edema: Pathophysiology